Algert Global’s Keros Therapeutics KROS Stock Holding History

Algert Global’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-193,607	Closed	-$3.94M	–	1257
2025 Q4	$3.94M	Buy	193,607 +145,828	+305%	+$2.56M	0.06%	520
2025 Q3	$756K	Sell	47,779 -7,791	-14%	-$115K	0.01%	875
2025 Q2	$742K	Buy	55,570 +28,090	+102%	+$379K	0.02%	863
2025 Q1	$280K	Buy	27,480 +14,783	+116%	+$172K	0.01%	1025
2024 Q4	$201K	Buy	12,697 +2,617	+26%	+$136K	﹤0.01%	1076
2024 Q3	$585K	Sell	10,080 -5,620	-36%	-$278K	0.02%	870
2024 Q2	$717K	Buy	15,700 +1,505	+11%	+$80.9K	0.02%	776
2024 Q1	$940K	Buy	14,195 +3,560	+33%	+$211K	0.04%	627
2023 Q4	$423K	Hold	10,635	–	–	0.02%	866
2023 Q3	$339K	Sell	10,635 -5,960	-36%	-$223K	0.02%	857
2023 Q2	$667K	Hold	16,595	–	–	0.03%	752
2023 Q1	$709K	Buy	+16,595	New	+$838K	0.03%	744

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Algert Global's KROS Position: Q1 2026 in Review

Algert Global sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 193,607 shares — an estimated $3.94M sold.

Algert Global first reported a position in KROS in Q1 2023 and held it in 12 quarters. The position peaked at $3.94M in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

Algert Global reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
Algert Global sold 193,607 Keros Therapeutics shares in Q1 2026, an estimated $3.94M.
Algert Global first reported a position in Keros Therapeutics in Q1 2023 and held it in 12 quarters.
Algert Global's Keros Therapeutics position peaked at $3.94M in Q4 2025.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.